Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.

The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with ...

Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals’ shares to stretch its cash runway, while also inking a share ...

Arrowhead Pharmaceuticals stock tumbled Thursday after Sarepta Therapeutics liquefied its entire stake in the smaller biotech ...

Sarepta Therapeutics, the US biotech, has sold around 9.3 million shares of Arrowhead Pharmaceuticals in a privately ...

Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline ...

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) stock fell 6% following Sarepta Therapeutics’ (NASDAQ:SRPT) sale of over 9.2 ...

It is a rough day to be an investor in Arrowhead Pharmaceuticals (NASDAQ: ARWR). Shares of the clinical-stage biotech are collapsing, falling more than 65% as of 11:36 a.m. EST on Tuesday in ...

What happened Shares of clinical-stage biotech company Arrowhead Pharmaceuticals (ARWR -0.97%) were up more than 17% Tuesday morning after the company released interim results from a phase 1/2 trial.

If so, you'll want to check out Arrowhead Pharmaceuticals (ARWR -6.03%). SVB Securities, a subsidiary of SVB Financial, recently gave the stock an upgrade to outperform and raised its price target.

Arrowhead Pharmaceuticals (NASDAQ: ARWR), a company that focuses on the treatment of intractable diseases by targeting the genes that cause them, has seen its stock rise by over 30% over the last ...

Arrowhead Pharmaceuticals Could Be A Quick And Easy Double Up From Here Aug. 17, 2020 11:08 AM ET Arrowhead Pharmaceuticals, Inc. (ARWR) Stock ARWR 31 Comments 27 Likes Trent Welsh 6.65K Follower s ...